Lung Cancer Clinical Trials
Lung Cancer clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for lung Cancer. Corterve aggregates actively recruiting Lung Cancer studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Lung Cancer studies
- Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)NCT06095583PHASE3Shanghai Junshi Bioscience Co., Ltd.Limited-stage Small Cell Lung Cancer (LS-SCLC)Goodyear, Arizona
- Personalized Accelerated ChEmoRadiation (PACER) for Lung CancerNCT06080061NAStanford UniversityLung CancerPalo Alto, California
- A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationNCT07566052PHASE3Astellas Pharma Global Development, Inc.Non-small Cell Lung Cancer (NSCLC)Glendale, California
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848PHASE3National Cancer Institute (NCI)Lung Non-Small Cell CarcinomaAnchorage, Alaska
- A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215PHASE3Hoffmann-La RocheNon-Small Cell Lung CancerAnchorage, Alaska
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung CancerNCT07659782PHASE2Verastem, Inc.Non-Small Cell Lung CancerLos Angeles, California
- Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialNCT06096844PHASE3National Cancer Institute (NCI)Advanced Lung Non-Small Cell CarcinomaFayetteville, Arkansas
- Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung LiningNCT00242723National Cancer Institute (NCI)Thoracic CancersBethesda, Maryland
- Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung CancerNCT07226999PHASE2, PHASE3PfizerSmall Cell Lung Cancer (SCLC)Fayetteville, Arkansas
- A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)NCT07488923PHASE1Moonlight Bio, IncSmall Cell Lung Cancer (SCLC )St Louis, Missouri
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialNCT06498635PHASE3National Cancer Institute (NCI)Lung Non-Small Cell CarcinomaJonesboro, Arkansas
- Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung CancerNCT06743308NAM.D. Anderson Cancer CenterLung CarcinomaHouston, Texas
Lung Cancer trials by state
Lung Cancer trials by metro
Frequently asked questions
- How do I find recruiting Lung Cancer clinical trials?
- Browse the actively recruiting Lung Cancer studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.
- Are Lung Cancer clinical trials free to join?
- Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.
- Who can take part in a Lung Cancer clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.